You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR061/#869  A retrospective study on the comparison of responsiveness of each chemotherapy for recurrent ovarian cancer after maintenance treatment with PARP inhibitors

Article Text

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS11. Ovarian cancer
PR061/#869  A retrospective study on the comparison of responsiveness of each chemotherapy for recurrent ovarian cancer after maintenance treatment with PARP inhibitors
Free
  1. Jung Chul Kim1,
  2. Junsik Park1,
  3. Yong Jae Lee2,
  4. Eunji Nam3,
  5. Sang Wun Kim1,
  6. Sunghoon Kim2,
  7. Young Tae Kim4 and
  8. Jung-Yun Lee1
  1. 1Yonsei University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of
  2. 2Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of
  3. 3Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Women’s Cancer Center, Yonsei Cancer Center, Institute of Women’s Life Medical Science, Seoul, Korea, Republic of
  4. 4Yonsei Cancer Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of

Abstract

Introduction In the SOLO2 trial, olaparib demonstrated a significant benefit in disease-free survival in platinum sensitive recurrent ovarian cancer patients with BRCA1/2 mutations, so importance and utility of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) in therapy is gradually increasing. However, there is no medical agreement for treatment after recurrence in ovarian cancer patients who have been administered PARPi, so they are generally treated with platinum-based chemotherapy that have been used previously, or undergo surgery and radiation therapy. Therefore, this study was conducted to confirm the efficacy of each chemotherapy for recurrent ovarian cancer after using PARPi.

Methods This retrospective study collected the data on recurrent ovarian cancer patients who have used PARPi after platinum-based chemotherapy in front-line to forth-line and using next chemotherapy of Liposomal doxorubicin (PLD)+Carboplatin, Belotecan+Cisplatin and Gemcitabin+Carboplatin from January 01, 2012 to April 30, 2023. The primary endpoint was progression free survival(PFS) from the date of disease progression after using PARPi to the date of next disease progression after using those chemotherapy methods.

Results There was a significant different PFS ( p value = 0.0367 ) in the three groups. And overall, the Gemcitabin+Carboplatin group showed better results than the other two groups, in particular, a significant difference with the PLD+carboplatin group ( p value = 0.0060, Hazard ratio : 2.964, 95% CI 1.128–7.791 ).

Conclusion/Implications In the treatment of recurrent ovarian cancer using platinum-based chemotherapy and PARPi, Gemcitabin + Carboplatin chemotherapy may show slightly better results than other chemotherapies, so additional research on this seems necessary.

Abstract PR061/#869 Figure 1
Abstract PR061/#869 Figure 1

Schema

Abstract PR061/#869 Figure 2
Abstract PR061/#869 Figure 2

Progression free survival(PFS) in among three chemotherapies

https://doi.org/10.1136/ijgc-2023-IGCS.101

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.